Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

194 ta ish

Ish: An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies

  1. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Sharh maqola20257 iqtibos
    ABI

  2. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Maqola20215 iqtibos
    ABI

  3. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Maqola20224 iqtibos
    ABI

  4. The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors

    Xiangping Li, Jian Qu, Xin-Qi Teng +4

    Sharh maqola20233 iqtibos
    ABI

  5. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Maqola20213 iqtibos
    ABI

  6. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos +80

    Sharh maqola20223 iqtibos
    ABI

  7. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

    Larysa Sanchez, Yucai Wang, David S. Siegel +1

    Sharh maqola20162 iqtibos
    ABI

  8. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

    Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Jihye Park +33

    Maqola20202 iqtibos
    ABI

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Mattia D’Agostino, David A. Cairns, Juan José Lahuerta +28

    Maqola20222 iqtibos
    ABI

  10. Multiple myeloma

    Florent Malard, Paola Neri, Nizar J. Bahlis +5

    Sharh maqola20242 iqtibos
    ABI

  11. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis

    Li Lan, Yeqi Sun, Jia Luo +1

    Maqola20242 iqtibos
    ABI

  12. Plasma cell neoplasms and related entities—evolution in diagnosis and classification

    Falko Fend, Ahmet Doǧan, James R. Cook

    Sharh maqola20222 iqtibos
    ABI

  13. Monoclonal Gammopathy of Undetermined Significance

    Wilson I. Gonsalves, S. Vincent Rajkumar

    Sharh maqola20222 iqtibos
    ABI

  14. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau +9

    Maqola20072 iqtibos
    ABI

  15. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquín Martínez‐López, Juan José Lahuerta, François Pépin +21

    Maqola20142 iqtibos
    ABI

  16. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

    S. Vincent Rajkumar, Robert A. Kyle, Terry M. Therneau +7

    Maqola20052 iqtibos
    ABI

  17. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

    Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung +1

    Boshqa20162 iqtibos
    ABI

  18. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

    Leo Rasche, Shweta S. Chavan, Owen Stephens +19

    Maqola20172 iqtibos
    ABI

  19. Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

    Alessandro Allegra, Vanessa Innao, Andrea Gaetano Allegra +5

    Sharh maqola20192 iqtibos
    ABI

  20. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Elı́as Campo, Elaine S. Jaffe, James R. Cook +70

    Maqola20222 iqtibos
    ABI

  21. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

    Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini +26

    Maqola20222 iqtibos
    ABI

  22. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig +25

    Maqola20222 iqtibos
    ABI

  23. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

    Tomáš Jelı́nek, Renata Bezděková, David Žihala +27

    Maqola20222 iqtibos
    ABI

  24. Chromosomal defects in multiple myeloma

    Sarah E. Clarke, Kathryn A. Fuller, Wendy N. Erber

    Sharh maqola20242 iqtibos
    ABI

  25. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu +34

    Maqola20242 iqtibos
    ABI